MedTrace Logo

Mpox Comprehensive Assessment for Responsive Immunisation in Emergency Outbreaks

NCT06887556 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 650

Last updated 2025-03-20

No results posted yet for this study

Summary

The MPXV CARE study principally aims to use clinical and epidemiology data to target specific individuals willing and able to provide appropriate and proportionate biological samples to develop novel immune diagnostics that support models of disease burden and future vaccine utilisation.

Conditions

Interventions

DIAGNOSTIC_TEST

ELISA

Mpox-specific antibody ELISA

DIAGNOSTIC_TEST

Lateral flow assay

Dried blood spot lateral flow assay for Mpox antibody

Sponsors & Collaborators

  • Rwanda Biomedical Centre

    collaborator OTHER

  • University of Birmingham

    lead OTHER

Principal Investigators

  • Christopher Green · University of Birmingham

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
5 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-05
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Rwanda

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06887556 on ClinicalTrials.gov